The FOXL2 antibody is a crucial tool in studying the FOXL2 protein, a transcription factor encoded by the *FOXL2* gene located on chromosome 3q22.3. FOXL2 plays a pivotal role in ovarian development, follicle maturation, and maintenance of ovarian function throughout reproductive life. Mutations in *FOXL2* are linked to blepharophimosis-ptosis-epicanthus inversus syndrome (BPES), characterized by eyelid malformations and, in some cases, premature ovarian insufficiency. Additionally, a somatic *FOXL2* mutation (c.402C>G) is a hallmark of adult-type granulosa cell tumors (AGCTs), making FOXL2 a diagnostic marker for these malignancies.
FOXL2 antibodies are widely used in research and diagnostics to detect FOXL2 expression via techniques like immunohistochemistry (IHC), Western blotting, or immunofluorescence. In research, these antibodies help elucidate FOXL2's regulatory roles in ovarian biology, steroidogenesis, and cell cycle control. Clinically, FOXL2 IHC aids in distinguishing AGCTs from other ovarian tumors, improving pathological accuracy. The antibody's specificity for FOXL2 ensures reliable identification of its nuclear localization, critical for validating its functional or pathogenic roles. However, antibody validation is essential, as cross-reactivity or batch variability can affect results. Overall, FOXL2 antibodies remain indispensable for advancing reproductive biology and gynecologic cancer research.